Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors and Lymphoma

NCT03272256 is registered in ClinicalTrials.gov with ImmunoMet Therapeutics, Inc. as lead sponsor.

NCT NCT03272256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03272256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors and Lymphoma
Lead sponsor
ImmunoMet Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 9, 2017
Completion date
July 28, 2020
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor